![PDF) Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma PDF) Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma](https://i1.rgstatic.net/publication/293045147_Extensive_Use_of_Interventional_Therapies_Improves_Survival_in_Unresectable_or_Recurrent_Intrahepatic_Cholangiocarcinoma/links/56d83c4608aebe4638b44c71/largepreview.png)
PDF) Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma
Verlag Kiepenheuer & Witsch - Sibylle BRG und GRM-Verlegerin Kerstin GLBA ❤️ #grmbrainfuck | Facebook
Dr. Peter R. Seidensticker, MD - Vice President MCA, Modality Head CT / CV & Informatics - Bayer Pharmaceuticals | LinkedIn
Dr. Peter R. Seidensticker, MD - Vice President MCA, Modality Head CT / CV & Informatics - Bayer Pharmaceuticals | LinkedIn
![PDF) Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib PDF) Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib](https://i1.rgstatic.net/publication/357605597_Early_tumor_shrinkage_and_response_assessment_according_to_mRECIST_predict_overall_survival_in_hepatocellular_carcinoma_patients_under_sorafenib/links/61d60d35e669ee0f5c8a4859/largepreview.png)